logo
Plus   Neg
Share
Email

Roche Reports Accelerated FDA Approval Of Tecentriq Combination - Quick Facts

Roche (RHHBY.PK) announced the US FDA has granted accelerated approval to Tecentriq (atezolizumab) plus chemotherapy for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer in people whose tumours express PD-L1, as determined by an FDA-approved test. The indication is approved under accelerated approval based on progression-free survival. The company noted that the continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Separately, Roche announced US FDA approval of the VENTANA PD-L1 Assay as the first companion diagnostic to aid in identifying triple-negative breast cancer patients eligible for treatment with the Roche cancer immunotherapy Tecentriq (atezolizumab) plus chemotherapy.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Starbucks Inc. has announced changes to its Starbucks Rewards loyalty program, noting that the revamp will provide its members with more flexibility and choice when they redeem stars at the company's stores. Starting on April 16, all members of the Starbucks Rewards loyalty program will be able to earn and redeem Stars for Rewards immediately after they join the program. Payment processing giant Visa Inc. is seeking a Technical Product Manager with expertise in cryptocurrency and blockchain for its cryptocurrency team. The company has listed a job opening on San Francisco-based recruiting software firm SmartRecruiters to find the manager for Visa Fintech. IBM announced the launch of IBM Blockchain World Wire, a real-time global payments network, aiming to support payments and foreign exchange in more than 50 countries. The network provides real time clearing and settlement using both stable coin backed by U.S. dollars and cryptocurrency.
Follow RTT